K
Klaus Peter Bogeso
Researcher at Lundbeck
Publications - 52
Citations - 1920
Klaus Peter Bogeso is an academic researcher from Lundbeck. The author has contributed to research in topics: Agonist & Receptor. The author has an hindex of 22, co-authored 52 publications receiving 1869 citations.
Papers
More filters
Journal ArticleDOI
Synthesis and Positron Emission Tomography Evaluation of Three Norepinephrine Transporter Radioligands: [C-11]Desipramine, [C-11]Talopram and [C-11]Talsupram
Magnus Schou,Magnus Schou,Judit Sovago,Victor W. Pike,Balázs Gulyás,Klaus Peter Bogeso,Lars Farde,Christer Halldin +7 more
TL;DR: The data show that DMI, talopram and talsupram are inferior to existing radioligands for the study of brain NET with PET in vivo.
Patent
Benzofuran derivatives, their preparation and use
Kim Andersen,Mario Rottländer,Klaus Peter Bogeso,Henrik Pedersen,Thomas Ruhland,Robert Dancer +5 more
TL;DR: In this paper, a general formula for benzofuran derivatives having general Formula (I) was proposed for binding to the 5-HT1A receptor, where A is selected from (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), (21), (22), (23), (24), (25), (26), (
Journal ArticleDOI
X-ray structure based evaluation of analogs of citalopram: Compounds with increased affinity and selectivity compared with R-citalopram for the allosteric site (S2) on hSERT.
Sid Topiol,Benny Bang-Andersen,Connie Sanchez,Per Plenge,Claus J. Loland,Karsten Juhl,Krestian Larsen,Peter Bregnedal,Klaus Peter Bogeso +8 more
TL;DR: Examples of a series of Citalopram analogs, showing distinct structure-activity relationship at both sites that is independent of the SAR at the other site are provided, demonstrating the potential utility of the newly emerging X-ray structures within the neurotransmitter:sodium Symporter family for drug design.
Journal ArticleDOI
Exploration of insights, opportunities and caveats provided by the X-ray structures of hSERT.
TL;DR: In this paper, the authors explore the binding and migration of 5-HT at SERT and find multiple potential'stopover' sites for 5HT binding, including two (transmembrane S1 and extracellular vestibule S2) seen in the binding of the SSRI (S)-citalopram (S-Cit) to SERT, as well as other sites.
Journal ArticleDOI
Stereospecific and selective 5-HT2 antagonism in a series of 5-substituted trans-1-piperazino-3-phenylindans.
TL;DR: A series of 5-substituted derivatives was synthesized with the goal of obtaining stereospecific and selective, centrally acting 5-HT2 antagonists, and important differences in aromatic substitution effects are shown.